1. Immunology/Inflammation
  2. PD-1/PD-L1


Programmed death-1 (PD-1) is a receptor on T cells that has been shown to suppress activating signals from the T cell receptor when bound by either of its ligands, Programmed death-ligand 1 (PD-L1) or PD-L2. When PD-1 expressing T cells contact cells expressing its ligands, functional activities in response to antigenic stimuli, including proliferation, cytokine secretion, and cytotoxicity are reduced. PD-1/PD-Ligand interactions down regulate immune responses during resolution of an infection or tumor, or during the development of self tolerance.

Interference with the PD-1/PD-L1 interaction has also shown enhanced T cell activity in chronic infection systems. Chronic lymphocytic chorio meningitis virus infection of mice also exhibits improved virus clearance and restored immunity with blockade of PD-L1.

In addition to enhancing immunologic responses to chronic antigens, blockade of the PD-1/PD-L1 pathway has also been shown to enhance responses to vaccination, including therapeutic vaccination in the context of chronic infection.

PD-1/PD-L1 相关产品 (6):

Cat. No. Product Name Effect Purity
  • HY-19745
    BMS-202 Inhibitor 99.63%
    BMS-202 是 PD-1/PD-L1 蛋白-蛋白相互作用抑制剂,主要用于抗癌研究。
  • HY-19991
    PD1-PDL1 inhibitor 1 Inhibitor 99.85%
    PD1-PDL1 inhibitor 1是PD-1/PD-L1蛋白/蛋白相互作用的抑制剂,是一种免疫调节剂。
  • HY-P9903
    Nivolumab Inhibitor 98.54%
    Nivolumab 是一种 PD-1 抑制剂,用于晚期(转移性)非小细胞肺癌的研究。
  • HY-101093
    PD-1-IN-1 Inhibitor 98.48%
    PD-1-IN-1是PD-1的抑制剂, 来自专利WO 2015033299 A1,化合物实例4。
  • HY-P9904
    Atezolizumab Inhibitor 98.71%
    Atezolizumab 是一种人源化单克隆抗体 IgG1,抵抗程序性死亡因子配体1 (PD-L1),用于癌症研究。
  • HY-P9902
    Lambrolizumab Inhibitor 98.56%
    Lambrolizumab 是一种人源化抗体,为 PD-1 的抑制剂,用于癌症免疫的研究。